Florida is currently home to 3785 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Recruiting
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/14/2025
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Breast Cancer
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Recruiting
The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Bay Pines VA Healthcare System, Bay Pines, Florida
Conditions: Non-muscle-invasive Bladder Cancer
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Recruiting
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib or other Janus Kinase (JAK) inhibitors in participants with MF in Part 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Miami, Coral Gables, Florida
Conditions: Myelofibrosis
BBD Longitudinal Study of Osteogenesis Imperfecta
Recruiting
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, norm... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Osteogenesis Imperfecta
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Recruiting
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Myeloma
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
Recruiting
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
05/13/2025
Locations: AMR Fort Myers, Fort Myers, Florida
Conditions: RSV Infection
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Recruiting
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining), or HER2-null breast cancer (BC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida
Conditions: Advanced Breast Cancer, Metastatic Breast Cancer
Study of OP-3136 in Advanced or Metastatic Solid Tumors
Recruiting
This is a first-in-human, open-label, multicenter phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.
Recruiting
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with moderate-to-severe asthma who have previously completed the parent study. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Qway Research - Hialeah- Site Number : 8400015, Hialeah, Florida
Conditions: Asthma
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Recruiting
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2025
Locations: Direct Helpers Research Center, Hialeah, Florida
Conditions: Prurigo Nodularis
Measuring Aided Language Development
Recruiting
The focus of the current study is to systematically investigate the psychometric properties of a range of aided language measures, which are based on the Graphic Symbol Utterance and Sentence Development Framework (Binger \& Kent-Walsh).
Gender:
ALL
Ages:
Between 42 months and 60 months
Trial Updated:
05/13/2025
Locations: University of Central Florida - Innovative Center, Orlando, Florida
Conditions: Down Syndrome, Cerebral Palsy, Apraxia of Speech, Speech Sound Disorder, Speech Disorders in Children, Speech and Language Disorder